ZBTB21 Antibody

What is ZBTB21 and why is it significant in research?

ZBTB21 (also known as ZNF295) is a zinc finger and BTB domain-containing transcription factor that functions primarily as a transcriptional repressor. Its significance stems from several key biological roles:

• Acts as a transcriptional repressor that specifically binds to cAMP-response element (CRE) DNA motifs and competes with CRE-binding factors such as CREB

• Suppresses CRE-dependent gene transcription, negatively regulating synaptic plasticity, learning, and memory

• Located within the Down syndrome critical region (DSCR) on chromosome 21, making it relevant to Down syndrome pathogenesis

• Highly expressed in brain tissues, particularly in neurons and astrocytes, with overexpression linked to cognitive deficits

• Contains 1 BTB (POZ) domain and 8 C2H2-type zinc fingers, suggesting its involvement in complex transcriptional regulation networks

Research interest in ZBTB21 has increased significantly since recent studies demonstrated its role in Down syndrome-associated synaptic dysfunction and cognitive impairment.

What types of ZBTB21 antibodies are currently available for research?

Several types of ZBTB21 antibodies are available for research applications:

• Rabbit polyclonal antibodies: The most common type, generated against specific regions of the ZBTB21 protein

• ChIP-certified antibodies: Specifically validated for chromatin immunoprecipitation applications to study ZBTB21's DNA binding properties

• Immunofluorescence-validated antibodies: Optimized for cellular localization studies

According to available product information, there are at least 86 different ZBTB21 antibodies across 17 suppliers, with varying specifications for different experimental applications .

What are the optimal applications for ZBTB21 antibodies?

ZBTB21 antibodies have been validated for multiple experimental applications:

The choice of application should be guided by the specific research question and the validation data available for the particular antibody.

How can ZBTB21 antibodies be used to detect different ZBTB21 isoforms?

ZBTB21 exists in at least two splicing variants (long and short forms) . When designing experiments to detect specific isoforms:

• Western blot analysis: Can detect different isoforms based on molecular weight differences

  • The canonical human ZBTB21 protein has a reported length of 1066 amino acid residues and a mass of 118.9 kDa

  • Multiple bands may be observed corresponding to different isoforms or post-translationally modified versions

• Isoform-specific detection strategy:

  • Review the epitope information of your antibody to determine which isoforms it will recognize

  • In experiments with ZBTB21 overexpression, both isoforms can be detected by Western blotting, showing two distinct bands

  • When using cDNA of specific ZBTB21 variants in experimental systems, consider that the long variant cDNA can lead to splicing, resulting in the detection of both forms

How should ZBTB21 antibodies be stored and handled for optimal performance?

Based on manufacturer recommendations for ZBTB21 antibodies:

• Storage conditions:

  • Store lyophilized antibody at -20°C or below

  • After reconstitution, aliquot and store at -20°C

  • Avoid multiple freeze-thaw cycles which can decrease antibody activity

• Reconstitution protocol:

  • For lyophilized antibodies in PBS buffer with 2% sucrose, add 50 μL of distilled water

  • This typically results in a final antibody concentration of 1 mg/mL

• Working solution preparation:

  • Dilute to appropriate concentration immediately before use

  • Prepare working solutions in buffer containing carrier protein (BSA) to minimize adsorption to surfaces

How can ZBTB21 antibodies be used to study its role in Down syndrome pathogenesis?

ZBTB21 antibodies can be instrumental in investigating its role in Down syndrome through several sophisticated approaches:

• Comparative expression studies:

  • Use antibodies to quantify ZBTB21 protein levels in brain tissues from individuals with Down syndrome compared to controls

  • Research shows that ZBTB21 expression is markedly elevated in excitatory neurons of individuals with Down syndrome

  • Cell type-specific expression analysis reveals that neurons with trisomy display the most pronounced increase in ZBTB21 levels

• Functional studies in mouse models:

  • ZBTB21 antibodies can be used to validate genetic manipulation in mouse models such as:

    • Dp16 mice (Down syndrome model) showing ZBTB21 overexpression

    • Dp16;Zbtb21+/− mice (with normalized Zbtb21 copy number)

    • Neuron-specific ZBTB21 overexpression models (Nestin-Zbtb21 or Camk2a-Zbtb21)

• Mechanistic investigation:

  • ChIP experiments using ZBTB21 antibodies can reveal genome-wide binding patterns and identify target genes affected by ZBTB21 overexpression

  • CUT&Tag-seq analysis combined with ZBTB21 antibodies has shown that ZBTB21 binding occurs within promoter regions, introns, and distal intergenic regions, with enrichment at CRE motifs

Can ZBTB21 antibodies differentiate between post-translationally modified forms of the protein?

ZBTB21 undergoes post-translational modifications, particularly SUMOylation, which affects its function:

• Detection of SUMOylated ZBTB21:

  • Western blot analysis using ZBTB21 antibodies can detect multiple bands corresponding to unmodified and SUMOylated forms of ZBTB21

  • Research has identified two evolutionarily conserved SUMOylation sites at lysine residues K419 and K845 (in zebrafish)

  • SUMOylated forms appear as higher molecular weight bands compared to unmodified ZBTB21

• Experimental approaches:

  • Co-immunoprecipitation experiments using anti-SUMO1 antibody followed by Western blotting with ZBTB21 antibody can specifically identify SUMOylated forms

  • Comparing wild-type ZBTB21 with SUMOylation site mutants (K419R, K845R, K419/845R) in Western blot analysis can help distinguish between differently modified forms

• Functional significance:

  • SUMOylation affects ZBTB21's transcriptional activity and subcellular localization

  • Using ZBTB21 antibodies in combination with functional assays can help correlate specific modifications with functional outcomes

How can ZBTB21 antibodies be used in ChIP experiments to study its binding to CRE elements?

ZBTB21 has been identified as a CRE-binding protein that represses CRE-dependent transcription. ChIP experiments with ZBTB21 antibodies can elucidate its genome-wide binding pattern:

• ChIP-seq methodology:

  • Use ChIP-certified ZBTB21 antibodies for immunoprecipitation of ZBTB21-bound chromatin

  • CUT&Tag-seq (Cleavage Under Target and Tagmentation sequencing) with ZBTB21 antibodies provides high-resolution mapping of binding sites

  • Analysis of ZBTB21-bound regions reveals enrichment at CRE motifs in promoter regions

• Target gene identification:

  • ChIP analysis using anti-HA antibody in HA-Zbtb21–overexpressing neurons has detected ZBTB21 binding to CRE elements in the promoters of learning and memory-related genes like Dcdc2a, Impact, and Crtcl

  • Combine with RNA-seq to correlate binding with transcriptional changes

• Competition studies:

  • ChIP experiments can investigate competitive binding between ZBTB21 and CREB at CRE sites

  • DNA pull-down assays with biotin-labeled CRE DNA fragments followed by Western blotting with ZBTB21 antibodies can confirm specific interactions

What are the key challenges in detecting ZBTB21 in different cell types or tissues?

Researchers may encounter several challenges when detecting ZBTB21 across various experimental systems:

• Variable expression levels:

  • ZBTB21 is widely expressed across tissues but with varying abundance

  • Particularly high expression in brain tissues, especially in neurons and astrocytes

  • Cell type-specific analysis may require optimization of detection protocols

• Detection specificity:

  • ZBTB21 has paralogs (e.g., ZBTB49) that may cross-react with some antibodies

  • Careful antibody selection and validation is crucial for specific detection

• Isoform complexity:

  • Multiple splicing variants exist, potentially complicating interpretation of results

  • Antibody epitope location determines which isoforms will be detected

• Post-translational modifications:

  • SUMOylation and potentially other modifications alter the molecular weight and may affect antibody recognition

  • Multiple bands may appear in Western blots, requiring careful interpretation

How can ZBTB21 antibodies be validated for high-confidence experimental results?

Rigorous validation ensures reliable results when working with ZBTB21 antibodies:

• Knockout/knockdown validation:

  • ZBTB21 knockout cells show enhanced FSK-induced CRE-dependent gene transcription

  • This phenotype is eliminated by restoring ZBTB21 expression, providing a functional validation system

  • Compare antibody reactivity in wild-type versus ZBTB21 knockout or knockdown samples

• Overexpression validation:

  • Test antibody specificity using cells overexpressing tagged ZBTB21 (e.g., HA-ZBTB21)

  • Confirm that the antibody detects both endogenous and overexpressed protein

• Application-specific validation:

  • For Western blot: Verify that the antibody detects a protein of the expected molecular weight (approximately 118.9 kDa for canonical human ZBTB21)

  • For immunohistochemistry/immunofluorescence: Confirm specificity through peptide competition or genetic models

  • For ChIP applications: Validate enrichment at known ZBTB21 binding sites like CRE motifs

How might ZBTB21 antibodies contribute to therapeutic development for Down syndrome?

ZBTB21 antibodies may facilitate therapeutic research for Down syndrome in several ways:

• Target validation:

  • ZBTB21 has been identified as a contributor to synaptic dysfunction in Down syndrome

  • Normalization of Zbtb21 gene copy number in DS mice corrected deficits in cognitive performance, synaptic function, and gene expression

• Mechanism-based therapeutic approaches:

  • Research suggests that overcoming ZBTB21-mediated suppression of the cAMP-CREB pathway could benefit individuals with Down syndrome

  • Therapeutics that increase cAMP levels (like phosphodiesterase inhibitors or GnRH therapy) might compensate for ZBTB21-induced inhibition of CRE-dependent gene expression

  • ZBTB21 antibodies can be used to evaluate the molecular effects of such interventions

• Biomarker development:

  • ZBTB21 expression levels or activity could potentially serve as biomarkers for cognitive deficits in Down syndrome

  • Antibody-based assays could be developed to quantify ZBTB21 levels or activity in accessible samples

What emerging technologies might enhance the utility of ZBTB21 antibodies in research?

Several cutting-edge approaches could expand the application of ZBTB21 antibodies:

• Single-cell antibody-based technologies:

  • Combining ZBTB21 antibodies with single-cell technologies could reveal cell type-specific expression patterns and functions

  • Studies have already shown cell type-specific differences in ZBTB21 expression in the brain, with particularly high levels in excitatory neurons

• In vivo imaging:

  • Development of ZBTB21 antibody-based imaging probes could enable visualization of ZBTB21 expression or activity in living systems

  • This could provide insights into the temporal dynamics of ZBTB21 function during development or in disease models

• Proximity labeling approaches:

  • Combining ZBTB21 antibodies with proximity labeling techniques (BioID, APEX) could identify novel protein interaction partners

  • This may reveal previously unknown components of ZBTB21 regulatory networks

• High-throughput screening platforms:

  • ZBTB21 antibody-based assays could be developed for screening compounds that modulate ZBTB21 expression or activity

  • Such screens could identify potential therapeutic candidates for Down syndrome or other conditions where ZBTB21 dysfunction contributes to pathology